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HCV prevalence can predict HIV epidemic
potential among people who inject drugs:
mathematical modeling analysis
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Abstract
Background: Hepatitis C virus (HCV) and HIV are both transmitted through percutaneous exposures among people
who inject drugs (PWID). Ecological analyses on global epidemiological data have identified a positive association
between HCV and HIV prevalence among PWID. Our objective was to demonstrate how HCV prevalence can be
used to predict HIV epidemic potential among PWID.
Methods: Two population-level models were constructed to simulate the evolution of HCV and HIV epidemics
among PWID. The models described HCV and HIV parenteral transmission, and were solved both deterministically
and stochastically.
Results: The modeling results provided a good fit to the epidemiological data describing the ecological HCV and
HIV association among PWID. HCV was estimated to be eight times more transmissible per shared injection than
HIV. A threshold HCV prevalence of 29.0% (95% uncertainty interval (UI): 20.7-39.8) and 46.5% (95% UI: 37.6-56.6)
were identified for a sustainable HIV epidemic (HIV prevalence >1%) and concentrated HIV epidemic (HIV
prevalence >5%), respectively. The association between HCV and HIV was further described with six dynamical
regimes depicting the overlapping epidemiology of the two infections, and was quantified using defined and
estimated measures of association. Modeling predictions across a wide range of HCV prevalence indicated overall
acceptable precision in predicting HIV prevalence at endemic equilibrium. Modeling predictions were found to be
robust with respect to stochasticity and behavioral and biological parameter uncertainty. In an illustrative
application of the methodology, the modeling predictions of endemic HIV prevalence in Iran agreed with the scale
and time course of the HIV epidemic in this country.
Conclusions: Our results show that HCV prevalence can be used as a proxy biomarker of HIV epidemic potential
among PWID, and that the scale and evolution of HIV epidemic expansion can be predicted with sufficient
precision to inform HIV policy, programming, and resource allocation.
Keywords: HIV, Hepatitis C virus, People who inject drugs, Mathematical modeling, Prediction
Background
Prioritization of populations and settings for HIV pre-
vention interventions is critical to increase the cost-
effectiveness of programs [1]. This is particularly the
case in resource-limited settings such as most of the
Middle East and North Africa (MENA) where HIV
surveillance among most-at-risk populations, including
people who inject drugs (PWID), remains deficient [2].
In this region, emerging and sometimes rapidly rising
HIV epidemics have been recently documented among
PWID [3]. Identification of settings with high HIV epi-
demic potential among PWID would help in
prioritization and resource allocation for prevention in-
terventions before HIV prevalence reaches high endemic
levels. In this work, we provide the theoretical founda-
tion, and describe an application in MENA, for an in-
novative approach to identify PWID populations at high
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risk of future HIV epidemic expansion. The concept is
to use prevalence data on hepatitis C virus (HCV) to
predict HIV epidemic potential.
Both HCV and HIV are transmitted through percutan-
eous exposures, and among PWID, sharing of non-
sterile injecting equipment is the main mode of trans-
mission [4]. However, HCV is more transmissible than
HIV [5], has a higher prevalence, and is hyperendemic
in most PWID populations [6, 7]. Globally, 63% of
PWID are HCV infected [6, 7] while only 19% are HIV
infected [6]. A recent meta-analysis identified that 82%
of HIV-infected PWID are co-infected with HCV [8]. At
the individual level, with HCV being most often trans-
mitted before HIV along the same route of transmission,
it could be used as a marker of the risk of exposure to
HIV.
Few studies have investigated the association between
HCV and HIV among PWID [9–13]. Ecological analyses
on global [10] and MENA [9] epidemiological data have
identified a positive association between the two infec-
tions. The association was found to be most robust
when both infections are at endemic equilibrium [9],
and is characterized by a threshold effect whereby HIV
prevalence is likely to be negligible below a certain HCV
prevalence of about 30% [10]. Two mathematical model-
ing studies reproduced the epidemiological epidemic dy-
namics [11, 13]. They projected the presence of an HCV
threshold effect for a sustainable HIV epidemic; but the
value of this HCV threshold was found to be highly sen-
sitive to a number of behavioral parameters such as het-
erogeneity in risk, level of mixing, and duration of
injecting [11, 13]. The models were also able to repro-
duce, above the threshold, the diversity of HCV and HIV
epidemics occurring in different settings [11, 13]. These
models however, with the uncertainty in behavioral pa-
rameters, questioned the utility of HCV prevalence in
predicting HIV epidemic scale.
In this study, we re-examine the HCV-HIV association
among PWID using a modeling approach that accom-
modates stochasticity and a complex injecting contact
structure. We estimate the HCV thresholds for HIV epi-
demic expansion, and assess the extent to which this
threshold is affected by variations in behavioral and
HCV/HIV biological parameters. We also examine new
aspects in the HCV-HIV association that include 1) esti-
mating the HCV to HIV infectiousness ratio, 2) identify-
ing the different dynamical regimes in the overlapping
HCV-HIV epidemiology, and 3) developing and estimat-
ing summary measures that quantify the association be-
tween the two infections and that can be used, beyond
modeling, for predictions of HIV epidemic potential
among PWID. We further quantify the margins in HCV
predictability of HIV epidemic scale across a wide range
of HCV prevalence, through the conduct of uncertainty
analyses. Finally, an application is provided for one
MENA country where the HCV-HIV association is used
to predict the scale and evolution of the HIV epidemic.
Methods
HCV and HIV models structure
Two population-level compartmental models were con-
structed to simulate the evolution of HCV and HIV epi-
demics among PWID (Figs. 1 and 2, and Additional file
1). The models describe HCV/HIV parenteral transmis-
sion through sharing of non-sterile needles/syringes, and
were solved both deterministically and stochastically.
The deterministic versions of the models were expressed
each through a system of coupled nonlinear differential
equations, and stratified the PWID population into com-
partments according to HCV/HIV status, stage of HCV/
HIV infection, and level of injecting risk behavior. The
stochastic versions used the same transition rates in the
deterministic systems to generate the stochastic pro-
cesses. HIV progression in the HIV model was divided
into three stages: acute, latent, and advanced; while pro-
gression in the HCV model was divided into stages of
acute (primary infection), chronic, and secondary acute.
The latter denotes the acute phase following HCV re-
infection, in the event the primary infection was cleared.
Both the HCV and HIV models used the same inject-
ing behavior structure and parameter values. To accom-
modate heterogeneity in injecting risk behavior, we
stratified the PWID population into seven risk groups
with increasing level of injecting risk behavior. We as-
sumed that individuals become PWID at a constant rate
and remain in the same risk group until the end of their
injecting career or death. We also assumed that the dis-
tribution of the PWID population across the seven risk
groups follows a gamma distribution, as motivated by
previous theoretical and applied mathematical modeling
work [14–19] (Eq. 1 and Additional file 1).
p ið Þ ¼ 1
baΓ að Þ i
a−1e
−i
b ð1Þ
Here a is the shape parameter and b is the scale par-
ameter in the gamma distribution. With such a distribu-
tion, the majority of the PWID population belongs to
relatively lower risk groups while a small fraction be-
longs to the higher risk groups. PWID of different risk
groups interact according to a mixing matrix with a con-
tinuous spectrum between assortative (choosing inject-
ing partners from within their risk group) and
proportionate (choosing partners with no preferential
bias based on the type of risk group) mixing.
The level of risk behavior was modeled by the effective
partnership change rate. While expressed in units of
injecting partners per year, the effective partnership
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change rate is a complex summary measure of the overall
risk of exposure to HCV/HIV infections. It captures effect-
ively different factors that reflect the nature of injecting risk
behavior and networks, but are difficult to quantify, such as
clustering within networks, concurrency, and variability in
risk behavior [20–24]. Accordingly, the effective partnership
change rate reflects the distribution and strength of the risk
of exposure to HCV/HIV infection. Motivated by previous
mathematical modeling work [25–29], the distribution of
the level of injecting risk behavior, that is of the effective
partnership change rate, across the seven risk groups was
defined through the following power law function where
the level of risk behavior grows larger and larger with the
risk group number (Eq. 2 and Additional file 1):
ρPi ¼ Ciα ð2Þ
where α is the exponent in the power-law function
and C is an overall constant. The different HCV/HIV
epidemic scales were generated by changing the value of
the average effective partnership change rate in the
PWID population. Further details on model structure
can be found in Additional file 1.
Data sources and model fitting
The model parameters were derived using recent empir-
ical HCV/HIV natural history and epidemiology data, as
well as through model fitting for some of the parame-
ters. All HCV/HIV biological and behavioral parameter
values and their references are summarized in Add-
itional file 2. Further justification for the parameter
values are provided in Additional file 1, Section 4.
HCV and HIV model predictions were fitted to global
epidemiological HCV and HIV prevalence data among
PWID [10]. These data were identified in an earlier sys-
tematic review of literature and included 863 paired
HCV-HIV data points among PWID from 343 different
geographical areas in 61 countries [10]. The paired
Fig. 1 HCV mathematical model description, equations, and parameter definitions. The details pertaining to the force of infection can be found
in Additional file 1
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HCV-HIV prevalence data were then fitted to a statistical
segmented linear regression model, indicating a positive eco-
logical association between HCV and HIV prevalence [10].
Our modeling predictions of endemic HCV and HIV preva-
lence at various levels of injecting risk behavior were fitted
to this ecological statistical association describing the epi-
demiological global HCV-HIV data [10]. The main purpose
of the fitting was to determine the best-fit value for the
HCV/HIV infectiousness ratio (that is the ratio of the HCV
transmission probability per shared injection to that of
HIV), a biological parameter and not a population-specific
parameter. This fitting insured that our modeling predic-
tions describe the actual HCV-HIV association observed
empirically among PWID. The fitting was made in the range
of HCV prevalence of 40–60%, where there is the highest
volume of epidemiological data [10]. We used a nonlinear
least-square fitting method incorporating the Nelder-Mead
simplex algorithm as described in Lagarias et al. to find the
best fit [30]. The method, as well as most of our modeling
analyses, were implemented in MATLAB [31, 32].
In addition to the infectiousness ratio of HCV to HIV,
three other measures were derived through the optimum
fit to the global epidemiological data: The scale and
shape parameters of the gamma distribution of the
population across injecting risk groups, and the expo-
nent parameter of the power law distribution of the level
of injecting risk behavior across risk groups.
Plan of analysis
HCV thresholds for HIV epidemic expansion
Derivation After fitting to global epidemiological data,
we used the best-fit parameters in applying the HCV
and HIV models. As a first step, we examined the associ-
ation between the prevalence of the two infections in
broad epidemic scales by plotting, at endemic equilib-
rium, HIV prevalence as a function of HCV prevalence.
This was done by varying the average injecting risk be-
havior parameter (effective partnership change rate) and
generating endemic HCV and HIV prevalence for each
value of average injecting risk behavior, using the deter-
ministic versions of the models. The endemic HCV
prevalence at which the corresponding endemic HIV
prevalence became greater than 1% was identified as the
HCV threshold for sustainable HIV epidemic, and the
endemic HCV prevalence that corresponded to an en-
demic HIV prevalence of 5% was identified as the
threshold for concentrated HIV epidemic.
Sensitivity analysis We conducted extensive univariate
sensitivity analyses to explore the HCV-HIV associ-
ation at broad ranges of changes in each model par-
ameter, including not only plausible but also extreme
values that are not even seen empirically. We exam-
ined the sensitivity of our modeling predictions of the
HCV thresholds, for both sustainable and concen-
trated HIV epidemics, to variations in 1) the infec-
tiousness ratio of HCV to HIV, 2) several injecting
risk behavior parameters including: the degree of as-
sortative mixing, the scale and shape parameters of
the gamma distribution of the population across
injecting risk groups, the exponent parameter of the
power law distribution of the level of injecting risk
behavior, and the duration of injecting and 3) scale-
up of antiretroviral therapy (ART) among those eli-
gible for treatment. We assumed that all infected
Fig. 2 HIV mathematical model description, equations, and parameter definitions. The details pertaining to the force of infection can be found in
Additional file 1
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PWID in the advanced HIV stage and half of those in
the latent HIV stage would be eligible for ART treat-
ment, which corresponds roughly to a CD4 cell count
criterion for treatment of 500 cells/μl [33]. We as-
sumed that the efficacy of ART in reducing HIV
transmission among PWID is 100%, based on a clin-
ical trial of treatment for prevention and other obser-
vational data [34, 35]. We also assumed that, by
slowing disease progression, 100% coverage among
those eligible for ART would double the average dur-
ation from onset of infection to death among the
total HIV infected population. Wide ranges of values
for the parameters of the sensitivity analyses were
chosen to produce a broad range of epidemics.
Uncertainty analyses
Two separate multivariate uncertainty analyses were
conducted to specify ranges of uncertainty in the pre-
dicted HCV thresholds, for both sustainable and con-
centrated HIV epidemics, with respect to 1) biological
parameters and 2) behavioral parameters. The bio-
logical parameters that were varied included: the prob-
abilities of HCV and HIV transmission per shared
injection in each infection stage, the duration of each
HCV and HIV stage, and the proportions of virus clear-
ance for HCV primary infection and HCV reinfection.
The behavioral parameters that were varied included:
the duration of injecting, the degree of assortative mix-
ing, the scale and shape parameters of the gamma dis-
tribution of the population across risk groups, the
exponent parameter of the power law distribution of
the level of risk behavior, and the frequency of sharing
acts per partnership. These were the same set of pa-
rameters that were varied in all subsequent behavioral
uncertainty analyses (as discussed below).
The parameters of the uncertainty analyses were
varied within 20% of their point estimates (Additional
file 2). We implemented 5,000 runs of the determinis-
tic HCV and HIV models using Monte Carlo sam-
pling from uniform probability distributions for the
uncertainty in these parameters. Estimates for the
mean values and associated 95% uncertainty intervals
(UI) for the predicted HCV thresholds were deter-
mined by fitting a log-normal distribution to the
range of values as described elsewhere [36].
Overlapping epidemiology of HCV and HIV infections
We quantified the epidemiological association between
HCV and HIV among PWID using the risk ratio
(RRHCV/HIV) and odds ratio (ORHCV/HIV) of HCV preva-
lence to HIV prevalence. The two measures were de-
fined as follows:
RRHCV=HIV ¼ PHCV−PthresholdPHIV ð3Þ
ORHCV=HIV ¼ PHCV−Pthreshold1− PHCV−Pthresholdð Þ
 
=
PHIV
1−PHIV
 
ð4Þ
where PHCV is HCV prevalence, Pthreshold is the mini-
mum HCV prevalence for a sustainable HIV epidemic,
and PHIV is HIV prevalence.
HCV and HIV prevalence at endemic equilibrium,
RRHCV/HIV, and ORHCV/HIV were examined as a function
of the average injecting risk behavior, that is the effective
partnership change rate, to qualitatively and quantita-
tively describe the overlapping dynamics of the two in-
fections at variable epidemic scales.
Effect of behavioral uncertainty on HCV-based predictions
of HIV epidemic scale
Our overarching aim is to use the above observed asso-
ciation between HCV and HIV infections to predict the
future size of HIV epidemics using HCV prevalence. We
assessed the precision of HCV prevalence in predicting
HIV prevalence at endemic equilibrium by quantifying,
across the whole spectrum of HCV prevalence, the effect
of behavioral uncertainty on our modeling prediction of
HIV prevalence. For each value of HCV prevalence, in-
creasing in increments of 4%, we implemented 50 runs
of the deterministic model using the uncertainty analysis
methods described above. The new set of parameter
values was used to refit the model to the specific HCV
prevalence. We then compared, at each HCV prevalence
level, the difference between the baseline prediction of
HIV prevalence and the 50 predictions of HIV preva-
lence including the behavioral uncertainty.
Application to Iran
HIV epidemic size prediction We applied the concept
of using HCV prevalence to predict HIV epidemic scale
in Iran as an illustrative example. We applied the deter-
ministic version of the HCV model, and varied the aver-
age injecting risk behavior until the model generated the
observed HCV prevalence in Iran. This specific value of
the average injecting risk behavior was then used in ap-
plying the stochastic HIV model and predicting the time
course of the HIV epidemic in this country.
The predicted time course of the HIV epidemic was
compared to the observed HIV prevalence levels in the
two conducted nationally-representative surveillance
surveys among PWID in Iran [37, 38]. In addition to
these two quality national data points, there are close to
100 HIV point prevalence measures over time among
PWID in Iran [3]. These data show a clear trend for the
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HIV PWID epidemic which started its emergence in the
late 1990s, reached a peak around the year 2005, then
stabilized over the last decade or so at a national preva-
lence of about 15% [3] (Additional file 3). This large vol-
ume of HIV prevalence data was used to inform the
fitting in Iran by ensuring that it generates a result that
is in line with the trend described by the epidemiological
data. In the absence of nationally-representative HCV
prevalence data among PWID, we used the median, 25th
percentile, and 75th percentile of all available HCV
prevalence data in Iran, as identified in a recent system-
atic review of PWID in MENA [3], and therefore pro-
duced three predicted HIV epidemic time courses.
HIV prevalence at endemic equilibrium in Iran was
also predicted directly, by subtracting the HCV thresh-
old for sustainable HIV epidemic from each of the three
HCV prevalence levels (25th, 50th, or 75th percentile),
then dividing by the deterministically model-estimated
RRHCV/HIV corresponding to each HCV prevalence
level—that is using Eq. 3.
Effect of stochasticity Since epidemic stochasticity
could affect our modeling predictions by generating dif-
ferent HIV epidemic scales for the same HCV preva-
lence level, we examined the effect of stochasticity on
our predictions of HIV prevalence at endemic equilib-
rium and also on RRHCV/HIV and ORHCV/HIV in Iran. We
used the behavioral parameter values which correspond
to the HCV prevalence level (25th, 50th, or 75th percent-
ile) that agrees most with the observed HIV prevalence
data in Iran. We generated 5,000 stochastic epidemic
simulations and calculated the mean value and 95% UI
for the predicted HIV prevalence, RRHCV/HIV, and
ORHCV/HIV by fitting a log-normal distribution to the
range of values.
Uncertainty analyses We also examined the precision
of our predictions of the HIV epidemic course in Iran.
We conducted two separate multivariate biological and
behavioral uncertainty analyses, using the methods de-
scribed above, to specify the range of uncertainty in the
predicted HIV prevalence, RRHCV/HIV, and ORHCV/HIV
that correspond to the HCV prevalence level that agrees
most with the observed HIV prevalence data in Iran. At
each run, the model was refit to this specific HCV
prevalence.
Results
HCV to HIV infectiousness ratio
The HCV and HIV model projections provided a good
fit to the global epidemiological data describing the eco-
logical association between HCV and HIV among PWID
(Fig. 3). The optimum fitting value of the infectiousness
ratio of HCV to HIV was found to be 7.8 (Additional file
2), suggesting that HCV is about eight times more trans-
missible per shared injection than HIV.
Epidemiologic association and threshold effect
The fitted models were used to generate a broad
spectrum of HCV and HIV prevalence and their epi-
demiological overlap (Fig. 3). As shown in Fig. 3, the
predictions indicate a positive association between HCV
and HIV prevalence at endemic equilibrium, with a
threshold HCV prevalence of 27.9% for a sustainable
HIV epidemic (>1%) and 45.2% for a concentrated HIV
epidemic (>5%).
Based on results of the sensitivity analyses (Figs. 4 and
5), changes in the HCV/HIV infectiousness ratio and in
injecting risk behavior parameters within the specified
wide ranges had a rather small effect on the existence or
values of the HCV thresholds for sustainable and con-
centrated HIV epidemics. More specifically, there was a
large reduction in the HCV thresholds only when the
HCV/HIV infectiousness ratio was <7, while the effect
of higher values of this ratio on the HCV thresholds was
limited (Figs. 4 and 5 (a)). The HCV thresholds were
mildly sensitive to changes in the degree of assortative
mixing, except near the extremes of fully proportionate
Fig. 3 Relationship between HCV and HIV prevalence at endemic equilibrium among people who inject drugs, and model fitting to the
segmented linear regression statistical model that summarizes the global epidemiological data as derived by Vickerman et al. [10]
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or fully assortative mixing (Figs. 4 and 5 (b)). Similarly,
the HCV thresholds showed somewhat mild dependence
to variation in the exponent parameter of the power law
distribution of risk behavior, with a more pronounced
effect when the exponent was closer to one (Figs. 4
and 5 (e)). There were small and limited effects, re-
spectively, of the scale and shape parameters of the
gamma distribution of the population across risk
groups (Figs. 4 and 5 (c and d)). The duration of
injecting and ART scale up had likewise a rather
small effect on both thresholds. The effect of ART
was most pronounced at very high coverage of above
90% (Figs. 4 and 5 (f and g)).
Figure 6 shows our prediction and 95% UI of the HCV
thresholds per the uncertainty analysis including all be-
havioral parameters. Results indicate a mean HCV
threshold for sustainable and concentrated HIV epi-
demics of 29.0% (95% UI: 20.7-39.8) and 46.5% (95% UI:
37.6-56.6), respectively. The effect of the biological un-
certainly on the HCV thresholds was smaller with a
Fig. 4 Sensitivity analyses on the HCV threshold for sustainable HIV epidemic (HIV prevalence >1%). These graphs illustrate the effect, on the HCV
threshold for sustainable HIV epidemic, of the HCV/HIV infectiousness ratio (a), the degree of assortative mixing (b), the scale (c) and shape (d)
parameters of the gamma distribution of the population across risk groups, the exponent parameter of the power law distribution of risk
behavior (e), duration of injecting (f), and anti-retroviral therapy (ART) coverage (g). For each set of parameter values in these graphs, the average
injecting risk behavior was varied; endemic HCV and HIV prevalence for each value of average injecting risk behavior were generated; and the
HCV threshold for sustainable HIV epidemic was identified and plotted
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mean HCV prevalence of 27.5% (95% UI: 23.2-31.9) and
of 44.7% (95% CI: 39.8-49.4) for sustainable and concen-
trated HIV epidemics, respectively.
Overlapping epidemiology of HCV and HIV infections
The epidemiological overlap between HCV and HIV in-
fections among PWID is illustrated in Fig. 7. Six dynam-
ical epidemiological regimes were discerned based on
the qualitative behavior of the prevalence of both
infections, the RRHCV/HIV, and the ORHCV/HIV (Fig. 7).
The regimes are summarized in Table 1.
In regime I, both HCV and HIV infections are below
epidemic sustainability. In regime II, there is sustainable
HCV transmission but HCV prevalence is low scale
(below 30%); HIV is still below epidemic sustainability.
In regime III, HCV prevalence is in the range of
28–45%. At this stage, HIV passed into epidemic
sustainability but is below 5%, the threshold defining a
concentrated HIV epidemic. In regime IV, HIV is in a
Fig. 5 Sensitivity analyses on the HCV threshold for concentrated HIV epidemic (HIV prevalence >5%). These graphs illustrate the effect, on the
HCV threshold for concentrated HIV epidemic, of the HCV/HIV infectiousness ratio (a), the degree of assortative mixing (b), the scale (c) and
shape (d) parameters of the gamma distribution of the population across risk groups, the exponent parameter of the power law distribution of
risk behavior (e), duration of injecting (f), and anti-retroviral therapy (ART) coverage (g). For each set of parameter values in these graphs, the
average injecting risk behavior was varied; endemic HCV and HIV prevalence for each value of average injecting risk behavior were generated;
and the HCV threshold for concentrated HIV epidemic was identified and plotted
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concentrated state (prevalence 5–24%) since HCV
prevalence is already above the threshold for a concen-
trated HIV epidemic (HCV prevalence >45%). In regime
V, HCV prevalence is between 70 and 80%, and HIV
prevalence is large scale, in the range of 25–42%. In re-
gime VI where HCV prevalence is approaching max-
imum possible prevalence (100%), the HIV epidemic is
very large scale and eventually also approaches max-
imum possible prevalence (100%) (Fig. 7, Table 1).
These six epidemiological regimes are also reflected in
the trend and range of RRHCV/HIV and ORHCV/HIV. These
two measures of association become expressed only in
regimes III-VI where both infections are above epidemic
sustainability (Fig. 7, Table 1). In regime III, HCV epi-
demic expansion is substantially faster than that of HIV,
resulting in RRHCV/HIV and ORHCV/HIV of 3.7-3.5 and 4.1-
4.0, respectively. However, in subsequent regimes, HIV
epidemic expansion gradually catches up with HCV
Fig. 6 Estimated HCV thresholds for sustainable and concentrated
HIV epidemic among PWID. The error bars represent the upper and
lower bounds of the 95% uncertainty interval around the predicted
HCV prevalence
Fig. 7 Epidemiological overlap between HCV and HIV infections among people who inject drugs. These graphs describe the epidemiological
relationship between HCV and HIV infections by plotting endemic HCV and HIV prevalence (a), the risk ratio of endemic HCV to HIV prevalence
(RRHCV/HIV) (b), and the odds ratio of endemic HCV to HIV prevalence (ORHCV/HIV) (c), as a function of the average injecting risk behavior (effective
partnership change rate). Six epidemiological regimes linking HIV prevalence and HCV prevalence are discerned (a). The RRHCV/HIV (b) and ORHCV/
HIV (c) are displayed for regimes III-VI with sustainable epidemics for both infections
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epidemic expansion. This is reflected in the decreasing
trend in RRHCV/HIV and ORHCV/HIV which reach 1.8 and
2.3 by the end of regime IV, respectively; and 1.2 and 1.5
by the end of regime V, respectively. In regime VI where
both infections eventually reach maximum prevalence,
the RRHCV/HIV and ORHCV/HIV ultimately reach their final
asymptotic values (Fig. 7, Table 1).
Predicting HIV epidemic scale using HCV prevalence:
Effect of behavioral uncertainty
The effect of behavioral uncertainty on the prediction of
HIV epidemic scale (HIV prevalence) across a wide range
of HCV prevalence settings is shown in Fig. 8 and summa-
rized by HCV/HIV dynamical regime in Table 2. Overall,
20% uncertainty in behavioral parameters resulted in a
median of <1% and a maximum of <10% absolute HIV
prevalence difference with the baseline prediction for HIV
prevalence. The effect of behavioral uncertainty was negli-
gible in regimes I & II and increased with higher regimes,
until it reached a maximum in regimes IV and V with a
median HIV prevalence difference of 1.9% (IQR: 0.9–3.4%
and 0.9–3.8%, respectively) between the baseline predic-
tion of HIV prevalence and the prediction including be-
havioral uncertainty (Fig. 8, Table 2).
Case study: Iran
Predicting the time course of the HIV epidemic
Based on available studies among PWID in Iran, the me-
dian HCV prevalence is 43.4% (interquartile range (IQR)
35.1–59.4%) [3]. The predicted time course of the HIV
Table 1 Description of the dynamical regimes of the overlapping epidemiology of HCV and HIV infections among people who
inject drugs
HCV prevalence HIV prevalence RRHCV/HIV
ab ORHCV/HIV
ab
Range Description Range Description Range Range
Regime I <1% Below sustainability <1% Below sustainability .. ..
Regime II 1–28% Above sustainability - low scale HCV epidemic <1% Below sustainability .. ..
Regime III 28–45% Large scale HCV epidemic 1–5% Above sustainability threshold for HIV
epidemic expansion and below
concentration threshold
3.7-3.5 4.1-4.0
Regime IV 45–70% Large scale HCV epidemic 5–24% Concentrated HIV epidemic 3.5-1.8 4.0-2.3
Regime V 70–80% Very large scale HCV epidemic 24–42% Large scale HIV epidemic 1.8-1.2 2.3-1.5
Regime VI >80% Approaching maximum prevalence >42% Very large scale HIV epidemic
and approaching maximum prevalence
<1.2 <1.5
a We are reporting the range of RR and OR excluding those corresponding to the immediate vicinity of the HCV threshold for HIV sustainable transmission
b The RRHCV/HIV and ORHCV/HIV are reported in descending order to reflect the decreasing trend in the ratios as a function of injecting risk behavior as per Fig. 7
Fig. 8 Effect of behavioral uncertainty on the HCV predictability of HIV epidemic expansion. The graph displays, for each HCV prevalence level,
the difference between the baseline prediction of HIV prevalence and 50 random predictions of HIV prevalence, at this specific HCV prevalence
level, that accommodate behavioral uncertainty
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epidemic corresponding to each of these HCV preva-
lence levels is shown in Fig. 9 for three representative
stochastic model runs. The predicted scale and time evo-
lution of the HIV epidemic corresponding to the 75th
percentile of HCV prevalence agreed best with the ac-
tual time course of the HIV epidemic observed in Iran,
whereby two rounds of nationally-representative surveil-
lance surveys reported an HIV prevalence of 15.3% in
2006–7 [37] and 15.1% in 2010 [38]. An HIV prevalence
at endemic equilibrium of 14.5% was predicted by the
indicated stochastic run corresponding to 59.4% HCV
prevalence (Fig. 9). The HIV stochastic predictions at
the 25th percentile and median HCV prevalence levels
could not generate the observed HIV prevalence in Iran
as they are below or just at the threshold for concen-
trated HIV epidemic, respectively.
To illustrate a simpler method for predicting HIV en-
demic prevalence using HCV prevalence, HIV preva-
lence at endemic equilibrium in Iran was also predicted
using Eq. 3 involving the RRHCV/HIV as derived from the
deterministic modeling results presented above. As per
Fig. 7, we predicted a RRHCV/HIV of 2.5 for an observed
HCV prevalence of 59% in Iran, resulting in predicted
HIV prevalence of 13%. This value is comparable with
the 15% HIV prevalence currently observed among
PWID in this country [37, 38] and also with the value
predicted above in a representative stochastic run (Fig. 9).
Identical results were also obtained, as expected, when
we used Eq. 4 in terms of the ORHCV/HIV and its pre-
dicted value of 3.2 for HCV prevalence of 59% (Fig. 7).
Effect of stochasticity and behavioral and biological
uncertainty on the predicted epidemic time course
The effect of stochasticity and of behavioral and bio-
logical uncertainty on our modeling predictions of en-
demic HIV prevalence, RRHCV/HIV, and ORHCV/HIV in
Iran corresponding to an HCV prevalence of 59.4% are
shown in Additional file 4. Stochasticity generated a nor-
mal distribution of the natural log of HIV prevalence,
RRHCV/HIV, and ORHCV/HIV, with a mean of 14.3% (95%
UI: 13.0-15.5), 2.4 (95% UI: 2.2-2.6), and 3.1 (95% UI:
2.8-3.5), respectively. Uncertainty in behavioral parame-
ters generated a skewed distribution of the natural log of
HIV prevalence, RRHCV/HIV, and ORHCV/HIV, with a mean
of 12.1% (95% UI: 5.4-21.1), 2.6 (95% UI: 1.5-5.8), and
3.3 (95% UI: 1.7-8.0), respectively. Uncertainty in
Table 2 Effect of behavioral uncertainty on HCV predictions of HIV epidemic scale by HCV/HIV epidemiological regime
HCV prevalence (%) Predicted HIV prevalence (%) HIV prevalence prediction difference (%)a
Range Range Median IQR
Regime I <1 <1 N/A N/A
Regime II 1–28 <1 0.1 0.0-0.3
Regime III 28–45 1–5 1.1 0.6-1.7
Regime IV 45–70 5–24 1.9 0.9-3.4
Regime V 70–80 24–42 1.9 0.9-3.8
Regime VI >80 >42 1.7 0.8-3.9
All regimes 0.9 0.2-2.2
IQR interquartile range
a Difference between baseline prediction of HIV prevalence and prediction of HIV prevalence including behavioral uncertainty
Fig. 9 Representative stochastic simulations of HIV epidemic expansion at different HCV endemic prevalence levels among people who inject
drugs in Iran, and comparison with epidemiological data
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biological parameters generated a normal distribution of
the natural log of HIV prevalence, RRHCV/HIV, and
ORHCV/HIV, with a mean of 13.5% (95% UI: 10.5–17.4%),
2.3 (95% UI: 1.8-3.0), and 2.9 (95% UI: 2.2-3.9),
respectively.
Discussion
Our mathematical modeling approach reproduced the
epidemiologically-observed ecological association be-
tween HCV prevalence and HIV prevalence among
PWID [10]. We estimated that HCV infection is 7.8
times more infectious per shared injection than HIV,
and confirmed the existence of an HCV threshold for a
sustainable HIV epidemic, which we estimated at 29.0%.
We further estimated an HCV threshold of 46.5% for a
concentrated HIV epidemic. These thresholds were in-
dependent of the uncertainty in biological parameters,
and largely insensitive to the details of injecting risk be-
havior, except near extreme values of mixing pattern and
variation in risk behavior among the different risk
groups in a PWID population. The association between
HCV and HIV was further described with six distinct dy-
namical regimes depicting the overlapping epidemiology
of the two infections, and was quantified using defined
and estimated measures of association.
Our main aim was to use this association between
HCV and HIV to predict HIV epidemic potential using
HCV prevalence. We showed, across a wide range of
HCV prevalence settings, that behavioral uncertainty,
arising from our limited knowledge of the details of the
risk behavior environment in PWID, resulted in accept-
able difference compared with our modeling predictions
of HIV epidemic scale. This was demonstrated for data
from Iran, where our modeling predictions reproduced
the actual time course of the HIV epidemic, even in con-
text of epidemic stochasticity and biological and behav-
ioral uncertainty. All of these findings support our
hypothesis that HCV prevalence can be used to make at
least broad predictions of the future size of the HIV epi-
demic among PWID; and that these predictions can be
further refined by applying mathematical models at spe-
cific HCV prevalence levels and potentially also for spe-
cific risk behavior environments.
HCV is known to be more infectious per percutaneous
exposure than HIV, but the infectiousness ratio of the
two infections via the parenteral route has not been esti-
mated precisely. Evidence from needle-stick injury stud-
ies suggests that HCV is 4–10 times more transmissible
per percutaneous injection than HIV [39–42]. By fitting
our modeling approach to global epidemiological data
for HCV and HIV prevalence, we provided, using a very
different methodology, an independent estimate of the
HCV to HIV infectiousness ratio among PWID at 7.8,
which is in line with the above range.
The natural dynamics of our modeling approach gen-
erated a threshold behavior in the HCV-HIV association
and estimated, in agreement with epidemiological data
[10], a minimum HCV prevalence of about 30% below
which HIV prevalence would be negligible. Earlier mod-
eling work indicated that this threshold is dependent on
the risk environment and thus likely to vary by setting,
potentially explaining why some settings with similar
HCV prevalence may have varying HIV prevalence levels
[11, 13]. Because it is constrained by fitting to the
epidemiologically-observed HCV-HIV association, our
modeling did not lead to as wide variation in the value
of the threshold. Despite accounting for uncertainty in
biological and behavioral parameters, the HCV threshold
was estimated within a reasonable range that is sufficient
to inform policy and programming. Our modeling pre-
dicted that the HCV threshold of about 30% for a sus-
tainable HIV epidemic is likely to apply in most global
settings, except in unusual injecting settings where some
risk behavior features are not typical of the common
patterns of injecting networks.
One possible explanation for the diversity in HCV/
HIV epidemics observed above the sustainability thresh-
old could be that a number of the HIV epidemics glo-
bally may not have reached endemic equilibrium.
Analysis of HCV-HIV epidemiological data among
PWID has shown that the association between the two
infections is strongest in settings of established HIV epi-
demics where HIV has reached an endemic level [9]. In
MENA, for example, most HIV epidemics among PWID
are emerging and have not reached endemic equilibrium
[3]; this could be the case in other regions/settings
where HIV prevalence levels are not typical of HCV-
based predictions. Another possible explanation could
be established harm reduction programs that are differ-
entially effective in preventing HIV. This could be either
due to the higher biological transmissibility of HCV
compared to HIV, or because these programs were intro-
duced after HCV reached endemic equilibrium but be-
fore HIV started its epidemic expansion. One such
example is possibly Australia, a country with well-
established needle-syringe exchange programs and
where HIV prevalence has been low at about 1% despite
HCV prevalence of 50–70% [43, 44].
Prioritization of affected populations for prevention in-
terventions is tied to the potential for concentrated HIV
epidemics (HIV prevalence >5%). We therefore derived
the threshold HCV prevalence necessary for a concen-
trated HIV epidemic, which we estimated at about 45%.
The effect of this threshold is manifested in settings of
low intensity HIV epidemics where there is some HIV
transmission among PWID, but the level of injecting risk
behavior, as reflected by HCV prevalence of <45%, is not
high enough to sustain concentrated HIV epidemics.
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The diverse HIV epidemic dynamics within Afghanistan
provides an example of this threshold phenomenon
(Table 3). HCV prevalence among PWID in Jalalabad
and Mazar-i-Sharif (10–26%) is below the predicted sus-
tainability threshold for HIV, and indeed HIV prevalence
in these two cities has not exceeded 1% [45–47]. In
Kabul however, where HCV prevalence at 28–37% is
over the predicted sustainability threshold for HIV, but
below the predicted concentration threshold for HIV,
HIV prevalence, as expected, is in the range of 2–3%
[45–47]. In Herat nonetheless, the high HCV prevalence
of 49–70% is predicted to sustain a large concentrated
HIV epidemic, and as expected, HIV prevalence has in-
creased from 3% in 2007 to 13–18% in subsequent sur-
veys [45, 46] (Table 3).
Six epidemiological regimes incorporating the HCV
thresholds were discerned in describing the overlapping
epidemiology of HCV and HIV infections among PWID
(Figs. 7 and 8). In the first regime, the level of injecting
risk behavior is extremely low and does not sustain an
HCV nor HIV epidemic. In the second regime, the level
of injecting risk behavior is relatively low, but enough to
sustain a low scale HCV epidemic. With HIV being eight
times less transmissible than HCV, an injecting risk net-
work in this regime cannot sustain an HIV epidemic;
HIV spreads slowly and inefficiently at very low level
and is sensitive to stochastic fluctuations. In the third re-
gime, the level of risk behavior is above the threshold
needed to maintain a sustainable HIV epidemic, but is
still not high enough to maintain an HIV prevalence lar-
ger than 5%. In the fourth and apparently most common
regime globally [10], the level of risk behavior is substan-
tial, as reflected by an HCV prevalence of 45–70%, and
this level of risk behavior is large enough to maintain
concentrated HIV epidemics reaching up to about 25%
in HIV prevalence. In the fifth regime, HCV prevalence
increases very slowly with risk behavior as it has already
attained extreme values reflecting infection transmission
saturation (>70%). However, HIV prevalence increases
substantially even with very small increments in HCV
prevalence, resulting in large scale HIV epidemics. In
the last regime, HCV continues its very slow growth
with risk behavior, while HIV is still growing noticeably,
though at slower pace compared with the fourth regime.
In this last regime, both infections eventually reach max-
imum possible prevalence.
In sum, HIV epidemic behavior in a PWID population
can be broadly predicted based on the regime HCV
prevalence belongs to. Any public health intervention
aiming at reducing injecting risk behavior among PWID
(such as education and awareness programs) may, if suc-
cessful, shift endemic HCV and HIV prevalence levels to
a new regime where HCV will still be predictive of HIV
but according to the HCV-HIV association characterized
by the new regime (Fig. 7).
The boundaries of each of these six epidemiological
regimes were further described in our study by the
RRHCV/HIV and ORHCV/HIV, which were defined and esti-
mated to quantify the association between HCV and
HIV infections. The ranges of RRHCV/HIV and ORHCV/HIV
in each regime were found to be relatively narrow. For
example, in the fourth regime where a large fraction of
the HIV PWID epidemics worldwide belongs [10], the
RRHCV/HIV and ORHCV/HIV are relatively stable and hover
around a value of 3 (Fig. 7b and c, Table 1). This indi-
cates that when HCV prevalence is in the range of 45–
70%, HIV prevalence will be about three times smaller
than the observed HCV prevalence minus 27.9%, the
threshold HCV prevalence for a sustainable HIV epi-
demic (Eq. 3). We found that behavioral uncertainty,
and to a lesser extent biological uncertainty and stochas-
ticity, could affect the predicted values of the RRHCV/HIV
and ORHCV/HIV, but overall in a predictable way that
does not undermine their potential programmatic use to
Table 3 Illustration of the threshold effects in Afghanistan
Year HCV prevalence (%) Status HIV prevalence (%) Study
Jalalabad 2007 12.5 Below sustainability threshold 0.0 [47]
2012 9.5 1.0 [46]
Mazar-i-Sharif 2007 24.1 Below sustainability threshold 0.0 [47]
2009 25.5 1.0 [45]
2012 18.8 0.3 [46]
Kabul 2005-6 36.6 Above sustainability threshold &
below concentration threshold
3.0 [56]
2008 36.1 2.1 [57]
2009 37.1 3.2 [45]
2012 27.6 2.4 [46]
Herat 2007 49.1 Above concentration threshold 3.2 [47]
2009 57.9 18.2 [45]
2012 70.0 13.3 [46]
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characterize HCV-HIV overlapping epidemiology and to
make predictions of future HIV epidemic scale.
Our findings provide a rationale for using HCV preva-
lence as a predictor of future HIV epidemic scale in
PWID. This approach provides also several specific pre-
diction methods with different levels of precision. First,
the derived HCV thresholds can be used in conjunction
with observed HCV prevalence to predict, in a broad
term, whether a PWID population is likely or not to ex-
perience a sustainable or concentrated HIV epidemic
(such as in the example of Table 3). Second, linking a
PWID population with its epidemiological regime based
on HCV prevalence, that is one of the six epidemio-
logical regimes in Table 1, can provide a range for the
predicted future HIV prevalence. For example, a PWID
population with an HCV prevalence of 50% belongs to
regime IV and is therefore likely to experience an HIV
epidemic with an HIV prevalence in the range of 5–24%.
Third, a more precise HIV prevalence range can be esti-
mated using the derived RRHCV/HIV (or ORHCV/HIV)
range for each specific epidemiological regime and Eq. 3
(or Eq. 4). For example, the RRHCV/HIV in regime IV
ranges between 1.8 and 3.5. For a PWID population at
50% HCV prevalence, this RRHCV/HIV range translates,
through Eq. 3, into a predicted HIV prevalence range of
6–12%. Finally, the most precise estimation of HIV epi-
demic scale can be obtained by applying the mathemat-
ical models directly at a specific HCV prevalence. For a
50% HCV prevalence, modeling predicts an HIV preva-
lence of 7%. Uncertainty analyses can be also conducted
on the later estimate, using also the models, to provide
an uncertainty interval for this estimate, as was done for
Iran above.
There were several limitations in our study. Although
we used an elaborate mathematical model structure, we
may not have captured some of the complexities of
injecting risk networks and of HCV/HIV dynamics. For
example, we did not allow movement of PWID between
different risk groups, and did not incorporate the effect
of HCV-HIV co-infection and its potential effect on
HCV transmission and spontaneous clearance. We also
did not consider the sexual transmission of HIV since its
relative importance among PWID is small except among
specific sub-populations of PWID who are also men
who have sex with men or female sex workers [3, 10, 39,
48]. In most of MENA settings where our applications
are aimed at, the HIV epidemics are characterized by
limited sexual HIV transmission not only among PWID,
but even among populations at high risk of HIV sexual
transmission such as men who have sex with men
and female sex workers and their clients [49–52]. It
is therefore unlikely that sexual transmission of HIV
would affect our results and their applications in
MENA. Our model could be extended in future
research to include sexual HIV transmission where it
would be of value to estimate the relative contribu-
tion of sexual versus parenteral HIV transmission.
This would be especially relevant for applications of
the methodology to settings other than MENA where
sexual transmission may be more prominent.
The HIV model did not include scale-up of ART, but
ART coverage was included in a sensitivity analysis
where it had overall a minor effect on the HCV thresh-
olds except near extreme values of coverage (>90%).
Currently MENA has the lowest ART coverage of all re-
gions globally at 17% [30], with unpublished data sug-
gesting even lower coverage among PWID (World
Health Organization, unpublished). Similarly, and with
the very low coverage among PWID [53], the model did
not include the effect of HCV treatment. However, with
the newly available direct-acting antivirals to treat HCV,
scale-up of HCV treatment among PWID is expected to
increase, thus possibly influencing HCV transmission
dynamics and complicating the relationship between
HIV and HCV. In this case, our models would need to
be extended to capture HCV treatment scale up and
coverage, in addition to uneven healthcare services
among PWID, to adjust the modeling predictions of fu-
ture HIV prevalence based on existing HCV prevalence
levels.
Our modeling predictions can be also constrained by
limitations in the data input of our models. Nevertheless,
a wide range was attached to the biological and behav-
ioural parameters to capture the uncertainty in our
knowledge of these parameters. We also fitted our mod-
eling predictions to available global epidemiological data
[10] to derive key parameters that are not precisely mea-
sured, mainly the HCV/HIV infectiousness ratio. While
admittedly the epidemics in different global settings
could be in different stages, and not all epidemics of
substantial HCV and HIV prevalence are at equilibrium,
we fitted to all global data rather than to the temporal
trend of the epidemic in a specific setting, since the
main purpose was to derive this biological and not
setting-specific parameter. Also, fitting our dynamical
model to the actual epidemiological data and their time
series would have been superior to fitting to the regres-
sion line that summarizes these data [10]. Finally, pre-
dictions of HIV epidemic scale using the methodology
we propose will depend on the quality and representa-
tiveness of HCV prevalence data, in the same way any
other prediction method is dependent on the quality of
input data. This highlights the importance of collecting
quality and representative HCV prevalence data among
PWID.
Despite these limitations, we structured our models
through a parsimonious approach to ensure that the
models complexity is constrained by the available data,
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and predictions are robust even with broad ranges in
parameter values. Biological parameters in our model
are generally obtained from primary and most recent
empirical data, similar to comparable mathematical
modeling studies in the literature. Admittedly, behavioral
parameters have more uncertainty but the extensive sen-
sitivity and uncertainty analyses we conducted indicated
overall a minor effect on our model’s predictions of
HCV thresholds and endemic HIV prevalence. Our
model further fitted well the global epidemiological data
and was able to reproduce a number of the findings of
previous ecological and modeling work [9–11, 13].
Our findings, and the concept we present, have im-
portant policy, programming, and resource allocation
implications. We demonstrated that HCV can be used to
predict future HIV epidemics and their scale. Because of
stochasticity and biological and behavioural uncertainty,
predictions may not be very precise in terms of the exact
HIV prevalence foreseen. However even with coarse pre-
dictions, such an approach can be effective in pinpoint-
ing settings that are likely to experience substantial HIV
epidemics in the future, and accordingly need to be pri-
oritized for prevention interventions. In this sense, HCV
acts as a temperature scale of the level of risk behavior
in an injecting network, and can be used as an index to
measure the risk and severity of potential HIV epidemics
among PWID. This is, in essence, a population-based
diagnostic test or a screening approach, similar to other
individual-based diagnostic tests or public health screen-
ing programs, such as for heart disease or breast cancer.
While such diagnostics or screening programs may not
have perfect sensitivity or specificity for the disease of
interest, they have an important public health impact by
averting or controlling disease through early detection.
Moreover, studies have shown that identifying and tar-
geting most-at-risk populations significantly improve the
cost-effectiveness of interventions [1]. For example, a re-
cent study has indicated that by dividing the population
into two groups of high and low risk behavior, targeting
those at higher risk of acquiring HIV would increase the
effectiveness of an intervention (voluntary medical male
circumcision) ten-fold [54, 55]. By dividing the popula-
tion into six risk groups, the intervention becomes 80
times more effective if the highest risk group is targeted
compared to targeting the lowest risk group [54, 55].
Conclusions
We investigated and characterized the poorly-
understood association between HCV and HIV infec-
tions among PWID. The overlapping epidemiology of
the two infections was described using distinct dynam-
ical regimes and quantified with devised measures of as-
sociation. Despite the complexity of the models and of
the HCV-HIV association, these measures offered a
simple applied tool for policy makers and program offi-
cers to predict HIV epidemic potential in PWID popula-
tions. We also proposed several methods with varying
levels of precision for predicting HIV epidemic scale,
and this concept was demonstrated in a specific country,
Iran. The methodology proposed in the present study
has a practical relevance which can be disseminated dir-
ectly at the level of national stakeholders or in consult-
ation with the international organizations leading the
HIV/HCV response in the region, namely the World
Health Organization, Joint United Nations Programme
on HIV/AIDS, and the World Bank.
By identifying and targeting settings where HIV preva-
lence among PWID is currently at low level, but where
the level of risk behavior as reflected by HCV prevalence
is indicative of substantial future HIV epidemics, the
proposed methodology not only helps in prioritization of
PWID populations with high HIV epidemic potential,
but also will lead to higher cost-effectiveness of HCV/
HIV interventions. This is particularly critical in
resource-limited settings, such as MENA and other re-
gions in the world.
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